Scarica l'app Stockscreener
85.40
1.43%
1.20
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTGX Giù?
Forum
Previsione
Precedente Chiudi:
$84.20
Aprire:
$84.24
Volume 24 ore:
906.11K
Relative Volume:
0.78
Capitalizzazione di mercato:
$5.34B
Reddito:
$209.18M
Utile/perdita netta:
$52.04M
Rapporto P/E:
119.86
EPS:
0.7125
Flusso di cassa netto:
$37.10M
1 W Prestazione:
+0.93%
1M Prestazione:
+13.87%
6M Prestazione:
+86.38%
1 anno Prestazione:
+105.04%
Intervallo 1D:
$83.64
$86.67
Intervallo di 1 settimana:
$82.79
$86.95
Portata 52W:
$33.70
$93.25
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Nome
Protagonist Therapeutics Inc
Settore
Industria
Telefono
(510) 474-0170
Indirizzo
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Confronta PTGX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
85.40 | 5.26B | 209.18M | 52.04M | 37.10M | 0.7125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-12 | Iniziato | Leerink Partners | Outperform |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-12-06 | Iniziato | Goldman | Neutral |
| 2024-11-05 | Iniziato | Wedbush | Outperform |
| 2024-09-24 | Iniziato | TD Cowen | Buy |
| 2024-09-09 | Iniziato | Truist | Buy |
| 2023-10-30 | Iniziato | CapitalOne | Overweight |
| 2023-05-25 | Ripresa | Jefferies | Buy |
| 2022-08-25 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Buy |
| 2021-10-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-24 | Iniziato | Northland Capital | Outperform |
| 2021-01-06 | Iniziato | JP Morgan | Overweight |
| 2020-12-16 | Iniziato | Piper Sandler | Overweight |
| 2020-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-15 | Iniziato | Jefferies | Buy |
| 2020-05-18 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy |
| 2019-05-09 | Aggiornamento | Stifel | Hold → Buy |
| 2018-12-06 | Iniziato | Nomura | Buy |
| 2018-01-29 | Iniziato | Stifel | Buy |
| 2017-07-21 | Iniziato | BTIG Research | Buy |
Mostra tutto
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill - Times Herald
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting - Daily American
Envestnet Asset Management Inc. Grows Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics stock maintains Buy rating at Jefferies on pipeline potential - Investing.com Canada
What hedge fund activity signals for Protagonist Therapeutics Inc. stockWall Street Watch & Real-Time Chart Breakout Alerts - newser.com
How rising interest rates impact Protagonist Therapeutics Inc. stockRate Hike & Entry Point Strategy Guides - newser.com
How Protagonist Therapeutics Inc. stock responds to policy changesTrade Risk Summary & Weekly Top Gainers Trade List - newser.com
Is Protagonist Therapeutics Inc. stock entering bullish territoryCPI Data & Advanced Technical Analysis Signals - newser.com
What risks investors should watch in Protagonist Therapeutics Inc. stockEarnings Recap Report & Daily Oversold Stock Bounce Ideas - newser.com
Is Protagonist Therapeutics Inc. stock cheap compared to fundamentalsMarket Growth Summary & Weekly Top Gainers Trade List - newser.com
Protagonist Therapeutics (PTGX) Price Target Increased by 16.48% to 91.65 - MSN
Protagonist Therapeutics expands scope of peptide therapeutics - Traders Union
Protagonist Therapeutics, Inc. $PTGX is Knott David M Jr's 9th Largest Position - MarketBeat
Protagonist Therapeutics Opens with 27.21% Gain Amidst Market Decline - Markets Mojo
Persistent Asset Partners Ltd Takes Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by Bank of New York Mellon Corp - MarketBeat
H.C. Wainwright Reaffirms Their Buy Rating on Protagonist Therapeutics (PTGX) - The Globe and Mail
How Protagonist Therapeutics Inc. stock reacts to job market dataMarket Movement Recap & AI Powered Market Entry Strategies - newser.com
Protagonist Therapeutics, Inc. $PTGX Stock Holdings Trimmed by Aviva PLC - MarketBeat
November 2025's Top Value Picks For Potential Market Opportunities - Yahoo Finance
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by Jupiter Asset Management Ltd. - MarketBeat
Protagonist Therapeutics Inc. stock chart pattern explained2025 Trading Recap & Reliable Volume Spike Trade Alerts - newser.com
135,050 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Nan Fung Trinity HK Ltd. - MarketBeat
Profund Advisors LLC Has $1.05 Million Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
We Think You Can Look Beyond Protagonist Therapeutics' (NASDAQ:PTGX) Lackluster Earnings - 富途牛牛
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Central New Jersey News
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences - York Daily Record
How strong is Protagonist Therapeutics Inc. stock revenue growthEarnings Trend Report & Daily Profit Maximizing Tips - newser.com
Protagonist Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Market Performance - Markets Mojo
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $98.00 at Citigroup - MarketBeat
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Morris County NJ News | Daily Record
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress - Tallahassee Democrat
Citigroup Maintains Protagonist Therapeutics (PTGX) Buy Recommendation - Nasdaq
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Protagonist Therapeutics Inc Azioni (PTGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):